Company Overview
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Why Investors Should Care
Revenue has grown at a 48.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $10.02M (+121.6% YoY); net profit $-90.08M.
- Trailing 12 Months Year-on-year growth — revenue +472.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 48.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 48.11% |
| 1 Year: | 472.80% |
Stock Price Performance
| 1 Year: | -75.28% |
| 6 Months: | -55.30% |
| 3 Months: | +12.23% |
| 1 Month: | +6.12% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.21 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 48.1% over 5 years.
CONS
- Trading 77.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NYXH Nyxoah SA PHARMA | 1.56 | -0.62 | $158.87M | 0.00% | -119.32% | -122.68% | 48.11% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1.06M | 1.34M | 1.97M | 5.64M | 6.37M |
| Cost of Revenue | 406.00K | 490.00K | 779.00K | 2.02M | 2.73M |
| Gross Profit | 658.00K | 850.00K | 1.19M | 3.62M | 3.64M |
| Operating Expenses | 21.30M | 20.70M | 25.39M | 21.88M | 24.14M |
| Operating Income | -20.64M | -19.85M | -24.20M | -18.26M | -20.50M |
| EBITDA | -20.79M | -18.88M | -21.73M | -21.50M | -13.13M |
| Interest Expense | 694.00K | 677.00K | 700.00K | -380.00K | 705.00K |
| Pretax Income | -22.26M | -20.33M | -23.87M | -22.62M | -15.55M |
| Tax Provision | 125.00K | 278.00K | -290.00K | 895.00K | 390.00K |
| Net Income | -22.38M | -20.61M | -23.58M | -23.51M | -15.94M |
| Diluted EPS | -0.60 | -0.55 | -0.63 | -0.59 | -0.37 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 3.08M | 4.35M | 4.52M | 10.02M |
| Cost of Revenue | 1.15M | 1.66M | 1.55M | 3.69M |
| Gross Profit | 1.93M | 2.69M | 2.97M | 6.33M |
| Operating Expenses | 34.43M | 47.79M | 61.78M | 89.27M |
| Operating Income | -32.50M | -45.10M | -58.81M | -82.94M |
| EBITDA | -27.89M | -42.08M | -52.83M | -82.90M |
| Interest Expense | 237.00K | 217.00K | 886.00K | 1.69M |
| Pretax Income | -30.06M | -44.66M | -56.43M | -89.08M |
| Tax Provision | 1.17M | -1.45M | 2.80M | 1.01M |
| Net Income | -31.23M | -43.21M | -59.24M | -90.08M |
| Diluted EPS | -1.21 | -1.54 | -1.81 | -2.36 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 146.07M | 124.16M | 158.41M | 118.47M |
| Current Assets | - | 100.26M | 68.35M | 98.08M | 61.21M |
| Cash & Equivalents | - | 17.89M | 21.61M | 34.19M | 30.00M |
| Inventory | - | 882.00K | 3.31M | 4.72M | 4.66M |
| Receivables | - | 1.46M | 2.76M | 3.38M | 5.25M |
| Total Liabilities | - | 25.75M | 26.14M | 45.15M | 69.34M |
| Current Liabilities | - | 14.91M | 14.44M | 21.53M | 48.96M |
| Long Term Debt | - | 8.19M | 8.37M | 18.73M | 16.07M |
| Total Debt | - | 11.88M | 12.70M | 22.65M | 40.48M |
| Total Equity | - | 120.32M | 98.02M | 113.25M | 49.13M |
| Shares Outstanding | - | 25.85M | 28.67M | 37.43M | 43.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -28.76M | -44.78M | -49.23M | -68.98M |
| Investing Cash Flow | - | -89.95M | 32.01M | -16.32M | 28.33M |
| Financing Cash Flow | - | -983.00K | 16.86M | 77.44M | 38.11M |
| Capital Expenditure | - | -16.35M | -10.96M | -6.07M | -3.77M |
| Free Cash Flow | - | -45.10M | -55.74M | -55.30M | -72.75M |
| Net Change in Cash | - | -119.69M | 4.09M | 11.89M | -2.54M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 62.7% | 61.9% | 65.7% | 63.1% |
| Operating Margin % | -1,053.8% | -1,037.3% | -1,300.8% | -827.8% |
| Net Margin % | -1,012.5% | -993.8% | -1,310.2% | -899.1% |
| ROE % | -26.0% | -44.1% | -52.3% | -183.4% |
| ROCE % | -24.8% | -41.1% | -43.0% | -119.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 14.27% | 14.53M | $21.51M |
| 2 | BNP Paribas Asset Management Holding S.A. | 0.95% | 962.52K | $1.42M |
| 3 | Blackstone Inc | 0.90% | 921.50K | $1.36M |
| 4 | Axxion S.a. | 0.89% | 904.89K | $1.34M |
| 5 | Vestal Point Capital, LP | 0.83% | 843.46K | $1.25M |
| 6 | Heights Capital Management, Inc | 0.81% | 828.80K | $1.23M |
| 7 | Hudson Bay Capital Management Lp | 0.71% | 717.98K | $1.06M |
| 8 | Pentwater Capital Management Lp | 0.59% | 600.00K | $888.00K |
| 9 | Andera Partners | 0.51% | 522.06K | $772.64K |
| 10 | Readystate Asset Management LP | 0.20% | 207.47K | $307.06K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NYXH
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System BREATHE is scheduled to implant up to 229 patients at up to 25 U.S. centers, followed for up to five years, to evaluate the long-term saf…
Nyxoah Shares Jump After Genio Meets Primary Endpoints in CCC Patient Study
Nyxoah SA (NYXH) shares jumped 15% in Wednesday trading after it said its ACCCESS US pivotal study m
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients Reports an Apnea-Hypopnea Index (AHI) responder rate of 77.2% on a Ful…
Dr. Andrew Patel and Oath Surgical Bring Sleep Apnea Implant to Oregon in a First for Pacific Northwest Outpatient Surgery
SAN FRANCISCO, August 26, 2026--Oath Surgical today announced that Dr. Andrew Patel has performed the first of its kind implant procedure in Oregon and the first in the Pacific Northwest to take place in an ambulatory surgery center (ASC) s…
Information on the total number of voting rights and shares
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), August 25, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large s…
NYXH — Frequently Asked Questions
What is the current share price of Nyxoah SA (NYXH)?
As of 2026-09-19 21:16 PDT, Nyxoah SA (NYXH) trades at $1.56 on NasdaqGM. Its 52-week range is $1.31 to $6.80.
What is the market capitalisation of NYXH?
Nyxoah SA (NYXH) has a market capitalisation of $158.87M on NasdaqGM.
What is the P/E ratio of NYXH?
NYXH trades at a trailing price-to-earnings (P/E) ratio of -0.62. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.53.
What is the return on equity (ROE) of NYXH?
NYXH has a return on equity (ROE) of -122.68%. Its return on capital employed (ROCE) is -119.32%.
Is NYXH a good stock to buy?
This page provides a data-driven analysis of Nyxoah SA (NYXH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.